SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed
Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.
Transaction rows by code · counts, not monetary totals
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete
These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.
SEC issuer · 0001228627Opus Genetics, Inc.
No parent relationship is available in this import; this is not proof of independence.
Ocuphire Pharma, Inc. · former SEC name · 2020-11-09 to 2024-10-22
REXAHN PHARMACEUTICALS, INC. · former SEC name · 2005-05-16 to 2020-11-09
CORPORATE ROAD SHOW DOT COM INC · former SEC name · 2003-04-30 to 2005-04-29
FERRARO FRANK · former SEC name · 2003-04-29 to 2003-04-29
Revenue in constant purchasing power
USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.